Vogler, Sabine; Bauer, Eveli; Habimana, Katharina (2022): Centralised Pharmaceutical Procurement: Learnings from Six European Countries. Applied Health Economics and Health Policy, 20. pp. 637-650.

Full text not available from this repository.
Official URL (please open in a new browser tab/window): https://link.springer.com/epdf/10.1007/s40258-022-...


Several European countries have introduced centralised procurement for all or some medicines. This article comparatively describes key features of national centralised pharmaceutical procurement (CPP) systems of six European countries (Cyprus, Denmark, Estonia, Italy, Norway and Portugal). Additionally, it aims to identify benefits, challenges and prerequisites for successful CPP, with a view to offering learnings for other countries. Information was collected based on literature and interviews with national procurement experts. While all countries studied established a designated procurement entity, other institutional and organisational features of the CPP systems vary across the countries. All CPP systems apply a mix of procurement procedures depending on the type of medicine (mainly tendering and negotiations). Reported benefits of CPP include lower purchase prices, stronger bargaining power of the public purchasers, enhanced transparency and governance, improved equity, and eventually improved access to medicines. Challenges that are to be met particularly in the starting phase are opposition of some users and the management of stakeholders with different expectations. Issues such as limited competition and non-availability of medicines may continue in the CPP setting. Compliance with good procurement principles is indispensable for any procurement, including CPP. Further prerequisites for successful CPP include a consistent, comprehensive and regularly updated procurement strategy, sufficient funding and appropriate staffing of the procurement entity, efficient processes including contract management and logistics, data collection and monitoring as well as interaction with users and suppliers.

Item Type: Article
Subjects: OEBIG > Pharmaoekonomie
Date Deposited: 28 Sep 2022 15:20
Last Modified: 28 Sep 2022 15:20
URI: https://jasmin.goeg.at/id/eprint/2320